{"id":6185,"date":"2021-12-21T07:30:00","date_gmt":"2021-12-21T07:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/realheart-receives-sek-200000-funding-from-vinnova\/"},"modified":"2021-12-21T07:30:00","modified_gmt":"2021-12-21T07:30:00","slug":"realheart-receives-sek-200000-funding-from-vinnova","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/realheart-receives-sek-200000-funding-from-vinnova\/","title":{"rendered":"Realheart receives SEK 200,000 funding from Vinnova"},"content":{"rendered":"
Realheart has been granted an additional SEK 200,000 in funding from Vinnova within the "Medtech4Health: Competence strengthening in small businesses" programme. The grant will be used for continued blood testing in Realheart's laboratory.<\/strong><\/div>\n

Vinnova's aim with the initiative is to create conditions for international competitiveness and sustainable solutions to global societal challenges. Realheart has received funding from Vinnova in two earlier rounds. This new funding will be used for additional expertise to perform blood tests with pumps in clinical use. <\/span><\/span><\/span><\/span><\/p>\n

Heart failure is one of the most common causes of death in the world. Artificial hearts can save many lives. However, the alternative available so far has many serious blood-related complications resulting in few treated patients. An important step in the development of the next generation of artificial hearts is therefore to increase knowledge of how the pumps affect the blood, something Realheart is working on both in its own lab, in the blood lab created together with Karolinska University hospital and in collaborations with researchers around the world. <\/span><\/span><\/span><\/span><\/p>\n

''We are very grateful for this contribution. The support will allow us to further strengthen Realheart's competitiveness and continue this important work that is of great importance to the entire heart pump industry," said Realheart's CEO Ina Laura Perkins.<\/span><\/span><\/span><\/span><\/p>\n

\"\"<\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atriums and two chambers) which provides the opportunity to generate a physiologically adapted blood flow that mimics the body's natural circulation. A unique concept in the medical technology world.<\/span><\/em><\/span><\/span><\/span><\/p>\n<\/div>\n